Is There a Benefit of Addition Docetaxel, Abiraterone, Celecoxib, or Zoledronic Acid in Initial Treatments for Patients Older Than 70 Years With Hormone-sensitive Advanced Prostate Cancer? A Meta-analysis.
Sign Up to like & getrecommendations! Published in 2019 at "Clinical genitourinary cancer"
DOI: 10.1016/j.clgc.2019.05.001
Abstract: BACKGROUND Results from large randomized controlled trials combining docetaxel, abiraterone, celecoxib, or bisphosphonates with androgen deprivation therapy (ADT) in hormone-sensitive prostate cancer have emerged. However, in our knowledge, few data are available in patients older… read more here.
Keywords: docetaxel abiraterone; hormone sensitive; cancer; addition ... See more keywords